Alemtuzumab
- PDF / 169,620 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 75 Downloads / 156 Views
1 S
Adult onset still’s disease: case report A 37-year-old woman developed adult onset still’s disease (AOSD) during treatment with alemtuzumab for relapsing and remitting multiple sclerosis (RRMS). The woman was admitted to hospital with a 3-week history of fevers, flitting macular rash, sore throat and polyarthritis. Laboratory investigations demonstrated elevation in neutrophils and ferritin. She had underlying RRMS that went into remission following treatment with alemtuzumab [dosage and route not stated] six months previously. Despite receiving 72 hours of broadspectrum IV antibiotics [specific drugs not stated], fever and the associated symptoms did not improve. Immunology and microbiology tests returned negative. A CT scan of neck, chest abdomen and pelvis were unremarkable. Based on the findings, a diagnosis of AOSD, attributed to alemtuzumab was made [time to reaction onset not stated]. The woman was treated with prednisolone. Subsequently, an improvement was noted. By day 3 of prednisolone, ferritin level and neutrophil count improved, and ALP normalised. At the time of report, she was continued on slow weaning of steroids, and she remained asymptomatic. Narayan N, et al. Adult onset still’s disease as a novel autoimmune complication of alemtuzumab therapy: A case report and review of alemtuzumab associated autoimmune 803507343 disease. Rheumatology 59 (Suppl. 2): ii28 abstr. P23, Apr 2020. Available from: URL: http://doi.org/10.1093/rheumatology/keaa111.022 [abstract]
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
